MISSISSAUGA, Ontario,
June 29, 2018 /PRNewswire/
-- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX:
ARZ) ("Aralez" or the "Company") today
announced that, in connection with its review of strategic
alternatives, it entered into an Amendment (the "Amendment")
to that certain Second Amended and Restated Facility Agreement,
dated as of December 7, 2015, as
amended on October 3, 2016 (the
"Facility Agreement"), by and between the Company and
Deerfield Partners, L.P. ("Deerfield") and certain affiliates of each
party.
Pursuant to the terms of the Amendment, interest due and payable
on July 1, 2018 with respect to the
loans under the Facility Agreement will be paid in kind, added to
the outstanding principal amount of such loans and bear interest at
the applicable interest rate of such loans. The amount of
interest paid in kind and the interest thereon is due and payable
without premium or penalty on August 15,
2018 or such earlier date as loans maybe become due and
payable.
About Aralez Pharmaceuticals Inc.
Aralez
Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a specialty
pharmaceutical company focused on delivering meaningful products to
improve patients' lives while creating shareholder value by
acquiring, developing and commercializing products in various
specialty areas. Aralez's Global Headquarters is in Mississauga, Ontario, Canada and the Irish
Headquarters is in Dublin,
Ireland. More information about Aralez can be found at
www.aralez.com.
Cautionary Note Regarding Forward-Looking Statements
This press release includes certain statements that constitute
"forward-looking statements" within the meaning of applicable
securities laws. Forward-looking statements include, but are not
limited to, statements regarding the Company's exploration and
evaluation of range of strategic business opportunities to enhance
liquidity, but there can be no assurances that any such strategic
alternatives may available on reasonable terms or at all.
Forward-looking statements are typically identified by use of terms
such as "may," "will," "would," "should," "could," "expect,"
"plan," "intend," "anticipate," "believe," "estimate," "predict,"
"likely," "potential," "continue" or the negative or similar words,
variations of these words or other comparable words or phrases,
although some forward-looking statements are expressed
differently.
You should be aware that the forward-looking statements included
herein represent management's current judgment and expectations,
and are based on current estimates and assumptions made by
management in light of its experience and perception of historical
trends, current conditions and expected future developments, as
well as other factors that it believes are appropriate and
reasonable under the circumstances, but there can be no assurance
that such estimates and assumptions will prove to be correct and,
as a result, the forward-looking statements based on those
estimates and assumptions could prove to be incorrect. Accordingly,
actual results, level of activity, performance or achievements or
future events or developments could differ materially from those
expressed or implied in the forward-looking statements.
In addition, the Company's operations involve risks and
uncertainties, many of which are outside of the Company's control,
and any one or any combination of these risks and uncertainties
could also affect whether the forward-looking statements ultimately
prove to be correct and could cause the Company's actual results,
level of activity, performance or achievements or future events or
developments to differ materially from those expressed or implied
by the forward-looking statements. These risks include those
detailed from time-to-time under the caption "Risk Factors" and
elsewhere in the Company's Securities and Exchange Commission (SEC)
filings and reports and Canadian securities law filings, including
in the Company's Annual Report on Form 10-K for the year ended
December 31, 2017 and on Form 10-Q
for the three month period ended March 30,
2018, which are available on EDGAR at www.sec.gov, on SEDAR
at www.sedar.com, and on the Company's website at www.aralez.com,
and those described from time to time in the Company's future
reports filed with the SEC and applicable securities regulatory
authorities in Canada. You should
not place undue importance on forward-looking statements and should
not rely upon this information as of any other date. We undertake
no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, unless required by law.
Aralez Pharmaceuticals US Inc. Contact:
Christopher Bona
312-329-3918
info@aralez.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/aralez-enters-into-amendment-to-second-amended-and-restated-facility-agreement-300674951.html
SOURCE Aralez Pharmaceuticals Inc.